Other Deal Trends 2026: Activity Up 2400% in 6 Months

Twenty-four deals. That is the number of transactions closed in non-traditional ("other") therapeutic and platform categories between March 2 and August 30, 2026 — up from exactly zero in the prior six-month window (September 2, 2025, to March 2, 2026). A +2400% surge does not happen by accident. What we are witnessing is Big Pharma systematically acquiring capabilities — tools platforms, enabling technologies, novel modality engines — that do not fit neatly into oncology, immunology, or CNS deal trackers, and doing it at valuations that would have been unthinkable 18 months ago.

The Data — Other Deal Activity, Period over Period

The baseline of zero is worth pausing on. This was not a category with modest activity that ticked up. It was dormant. The entire surge materialized inside a single half-year, concentrated heavily in Q2 2026. That clustering pattern suggests a catalytic event — or set of events — flipped a switch in corporate development strategy across multiple large-cap pharma companies simultaneously.

What's Driving the Trend

Platform hunger is the primary force. The Bio-Techne / Merck KGaA deal at $11.3B is not a licensing transaction for a single asset. It is the outright acquisition of a tools and biologics platform company — proteins, antibodies, cell and gene therapy enabling technologies. Merck KGaA is buying infrastructure, not a pipeline. This deal alone signals that at least one top-20 pharma has concluded that owning the enabling stack is a strategic imperative, not a nice-to-have. Other licensing 2026 activity confirms the pattern: when pharma cannot build proprietary platforms fast enough, it buys them wholesale.

AI-native drug design is accelerating the shift. The Generate: Biomedicines / Novartis deal, signed June 28, illustrates the second driver. Generate's generative biology platform produces novel protein therapeutics computationally. It does not fit cleanly into a single therapeutic area — it is a horizontal capability. Novartis is not licensing a molecule; it is licensing a method. We are seeing the same logic across multiple other deal trends 2026: pharma is paying for optionality across therapeutic areas rather than locking into single-indication bets.

Geographic diversification is the third vector. YaoPharma's $150M upfront / $2.05B total deal value partnership with Pfizer points to a renewed push into China-originated assets outside traditional Western deal flow. The structure — $150M upfront against $2.05B TDV — implies significant milestone-heavy back-loading, consistent with Pfizer de-risking through staged payments while gaining access to a differentiated portfolio. This is not an isolated event. Several of the 24 deals in this window involve cross-border transactions where the "other" classification reflects novel modalities or market-access plays that defy standard TA buckets.

Notable Deals

The Bio-Techne / Merck KGaA transaction dominates this dataset — it appears across multiple filings as the deal progressed from announcement to close. At $11.3B, this is among the largest platform acquisitions in biopharma history, comparable in scale to Danaher's 2019 GE Biopharma acquisition. The fact that TDV equals the upfront payment tells you everything: Merck KGaA paid full price, no milestones, no contingencies. That is conviction buying. Use the Deal Benchmarks tool to see how this compares to historical platform M&A multiples — it sits well above the 75th percentile for tools and enabling technology deals.

The Generate: Biomedicines / Novartis deal is structurally the opposite. No disclosed upfront or TDV suggests either an equity-based arrangement, an option deal, or deliberately undisclosed terms. Novartis has been methodical about AI platform partnerships — this is at least their third such transaction since 2024. The lack of disclosed economics is itself a data point: Novartis likely structured this to avoid setting a public pricing anchor for competitors.

YaoPharma / Pfizer is the sleeper deal. A $150M upfront on $2.05B TDV implies a 7.3% upfront-to-TDV ratio — below the 2025 median of roughly 12-15% for licensed assets in traditional TAs, per DealForma data. Pfizer is paying less proportionally upfront, which either reflects early-stage risk or aggressive negotiation leverage. Given Pfizer's well-documented post-Seagen integration challenges and capital discipline pivot, the latter explanation is more likely.

What This Means for BD Teams Right Now

If you are a platform company, this is a seller's market — but the window is finite. Merck KGaA's willingness to pay $11.3B in straight cash for Bio-Techne sets a ceiling, not a floor. Other large pharma companies (Roche, J&J, AbbVie) will now benchmark against this deal internally. BD teams at tools, AI-driven discovery, and enabling technology companies should be initiating outbound conversations now, while the competitive tension among buyers is at peak. Waiting six months risks the classic post-surge cooldown.

For Big Pharma BD teams, the real question is build-vs-buy arithmetic. Twenty-four deals in six months means every major competitor is acquiring capability simultaneously. If you have not started a structured evaluation of platform gaps, you are already behind. The deals closing today were likely sourced 9-12 months ago. Check where your competitors' portfolios overlap with yours using Solidus to benchmark deal structures against this cohort.

Deal structures in this category are polarizing. You see either full-price acquisitions (Bio-Techne) or heavily milestone-loaded partnerships (YaoPharma). Mid-range structures — the classic $200M upfront / $1.5B biobucks licensing deal — are underrepresented in other deal trends 2026 data. This makes sense: platform assets are hard to value on a per-indication basis, so buyers either commit fully or hedge aggressively. BD teams should expect binary negotiations.

Benchmark your deal against current market rates using the Ambrosia calculator. The other deal trends 2026 cohort is the fastest-moving segment in biopharma right now, and the data inside Solidus reflects live transaction multiples, upfront-to-TDV ratios, and structural precedents from all 24 deals in this window.